Display options
Cite
Kuo YH, Lin CH, Shih CC, et al. Antcin K, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles. Evid Based Complement Alternat Med. 2016;2016:4867092doi: 10.1155/2016/4867092.
Kuo, Y. H., Lin, C. H., Shih, C. C., & Yang, C. S. (2016). Antcin K, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles. Evidence-based complementary and alternative medicine : eCAM, 20164867092. https://doi.org/10.1155/2016/4867092
Kuo, Yueh-Hsiung, et al. "Antcin K, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles." Evidence-based complementary and alternative medicine : eCAM vol. 2016 (2016): 4867092. doi: https://doi.org/10.1155/2016/4867092
Kuo YH, Lin CH, Shih CC, Yang CS. Antcin K, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles. Evid Based Complement Alternat Med. 2016;2016:4867092. doi: 10.1155/2016/4867092. Epub 2016 May 08. PMID: 27242912; PMCID: PMC4875994.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2016;2016:4867092. doi: 10.1155/2016/4867092. Epub 2016 May 08.

Antcin K, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects via Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in Muscles.

Evidence-based complementary and alternative medicine : eCAM

Yueh-Hsiung Kuo, Cheng-Hsiu Lin, Chun-Ching Shih, Chang-Syun Yang

Affiliations

  1. Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 40402, Taiwan.
  2. Department of Internal Medicine, Fengyuan Hospital, Ministry of Health and Welfare, Fengyuan District, Taichung 42055, Taiwan.
  3. Graduate Institute of Pharmaceutical Science and Technology, College of Health Science, Central Taiwan University of Science and Technology, No. 666 Buzih Road, Beitun District, Taichung 40601, Taiwan.

PMID: 27242912 PMCID: PMC4875994 DOI: 10.1155/2016/4867092

Abstract

The purpose of this study was to screen firstly the potential effects of antcin K (AnK), the main constituent of the fruiting body of Antrodia camphorata, in vitro and further evaluate the activities and mechanisms in high-fat-diet- (HFD-) induced mice. Following 8-week HFD-induction, mice were treated with AnK, fenofibrate (Feno), metformin (Metf), or vehicle for 4 weeks afterward. In C2C12 myotube cells, the membrane GLUT4 and phospho-Akt expressions were higher in insulin and AnK-treated groups than in the control group. It was observed that AnK-treated mice significantly lowered blood glucose, triglyceride, total cholesterol, and leptin levels in AnK-treated groups. Of interest, AnK at 40 mg/kg/day dosage displayed both antihyperglycemic effect comparable to Metf (300 mg/kg/day) and antihypertriglyceridemic effect comparable to Feno (250 mg/kg/day). The combination of significantly increased skeletal muscular membrane expression levels of glucose transporter 4 (GLUT4) but decreased hepatic glucose-6-phosphatase (G6 Pase) mRNA levels by AnK thus contributed to a decrease in blood glucose levels. Furthermore, AnK enhanced phosphorylation of AMP-activated protein kinase (phospho-AMPK) expressions in the muscle and liver. Moreover, AnK treatment exhibited inhibition of hepatic fatty acid synthase (FAS) but enhancement of fatty acid oxidation peroxisome proliferator-activated receptor α (PPARα) expression coincident with reduced sterol response element binding protein-1c (SREBP-1c) mRNA levels in the liver may contribute to decreased plasma triglycerides, hepatic steatosis, and total cholesterol levels. The present findings indicate that AnK displays an advantageous therapeutic potential for the management of type 2 diabetes and hyperlipidemia.

References

  1. Nat Med. 2002 Nov;8(11):1288-95 - PubMed
  2. Biochem J. 2000 Feb 1;345 Pt 3:437-43 - PubMed
  3. N Engl J Med. 1988 May 12;318(19):1225-30 - PubMed
  4. Evid Based Complement Alternat Med. 2011;2011:212641 - PubMed
  5. Int J Mol Sci. 2015 Oct 20;16(10):24983-5001 - PubMed
  6. Diabetes. 2003 Jun;52(6):1355-63 - PubMed
  7. J Biol Chem. 2001 Oct 19;276(42):38870-6 - PubMed
  8. FEBS Lett. 1987 Nov 16;224(1):224-30 - PubMed
  9. Biochem Soc Trans. 2005 Apr;33(Pt 2):346-9 - PubMed
  10. Circulation. 2007 Mar 27;115(12):1537-43 - PubMed
  11. J Clin Invest. 1997 Oct 15;100(8):2115-24 - PubMed
  12. Nature. 2000 May 25;405(6785):421-4 - PubMed
  13. J Endocrinol. 2014 Jan 08;220(2):T1-T23 - PubMed
  14. Am J Physiol Endocrinol Metab. 2006 Oct;291(4):E817-28 - PubMed
  15. Planta Med. 2004 Apr;70(4):310-4 - PubMed
  16. Diabetes. 1981 Dec;30(12):1000-7 - PubMed
  17. Arch Intern Med. 1994 Feb 28;154(4):441-9 - PubMed
  18. J Biol Chem. 2003 Sep 5;278(36):33609-12 - PubMed
  19. Diabetes. 2000 Apr;49(4):647-54 - PubMed
  20. J Agric Food Chem. 2014 Nov 5;62(44):10717-26 - PubMed
  21. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9 - PubMed
  22. Hepatology. 2005 Jun;41(6):1313-21 - PubMed
  23. Diabetes. 2004 Dec;53 Suppl 3:S215-9 - PubMed
  24. Mol Cell Biochem. 2006 Apr;285(1-2):35-50 - PubMed
  25. Circulation. 1998 Nov 10;98(19):2088-93 - PubMed
  26. Nature. 2002 Jan 17;415(6869):339-43 - PubMed
  27. Clin Sci (Lond). 2012 Mar;122(6):253-70 - PubMed
  28. Am J Physiol Cell Physiol. 2008 Nov;295(5):C1071-82 - PubMed
  29. Eur J Intern Med. 2003 Oct;14(6):357-360 - PubMed
  30. J Tradit Complement Med. 2015 Feb 04;6(1):48-56 - PubMed
  31. Cell Metab. 2007 Apr;5(4):237-52 - PubMed
  32. Metabolism. 2004 Apr;53(4):454-7 - PubMed
  33. J Clin Invest. 2001 Oct;108(8):1167-74 - PubMed
  34. Int J Mol Sci. 2014 Nov 04;15(11):20022-44 - PubMed
  35. Cell Growth Differ. 1999 Jan;10(1):43-8 - PubMed
  36. Eur J Pharmacol. 2002 Apr 12;440(2-3):223-34 - PubMed
  37. Diabetes. 2002 Jul;51(7):2074-81 - PubMed
  38. Mol Cell Endocrinol. 2005 Mar 31;232(1-2):37-45 - PubMed
  39. Horm Metab Res. 1999 Oct;31(10):570-5 - PubMed
  40. Molecules. 2013 Mar 01;18(3):2726-53 - PubMed
  41. J Ethnopharmacol. 2009 May 4;123(1):82-90 - PubMed
  42. J Nutr. 2006 Jul;136(7):1779-85 - PubMed
  43. Diabetes. 2005 Aug;54(8):2460-70 - PubMed
  44. Phytother Res. 2010 Dec;24(12):1769-80 - PubMed
  45. J Agric Food Chem. 2015 Mar 11;63(9):2479-89 - PubMed
  46. Biochemistry. 1989 May 30;28(11):4523-30 - PubMed
  47. J Biol Chem. 1999 Dec 10;274(50):35832-9 - PubMed
  48. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E685-92 - PubMed
  49. Diabetes. 2003 Feb;52(2):239-43 - PubMed
  50. Food Chem. 2013 Dec 1;141(3):3020-7 - PubMed
  51. Diabetes. 2007 Mar;56(3):836-48 - PubMed
  52. Med Sci Sports Exerc. 2004 Jul;36(7):1202-6 - PubMed
  53. Diabetes. 1996 Jul;45(7):988-91 - PubMed
  54. Diabetes Metab Res Rev. 2003 Jan-Feb;19(1):3-7 - PubMed
  55. Diabetes. 2013 Jul;62(7):2249-58 - PubMed
  56. Int J Obes Relat Metab Disord. 2000 May;24(5):639-46 - PubMed
  57. J Agric Food Chem. 2015 Nov 25;63(46):10140-51 - PubMed
  58. Chem Biol. 2008 Mar;15(3):263-73 - PubMed
  59. Nat Rev Mol Cell Biol. 2002 Apr;3(4):267-77 - PubMed
  60. J Agric Food Chem. 2003 Mar 12;51(6):1571-7 - PubMed
  61. Diabetes Metab Syndr Obes. 2014 Feb 13;7:55-64 - PubMed

Publication Types